Contraception
Volume 78, Issue 5 , Pages 377-383, November 2008

Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives☆

  • Jeanne Loughlin

      Affiliations

    • Ingenix i3 Drug Safety, Waltham, MA 02451, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 781 472 8460; fax: +1 781 472 8464.
    • ,
  • John D. Seeger

      Affiliations

    • Ingenix i3 Drug Safety, Waltham, MA 02451, USA
    • Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    • ,
  • P. Mona Eng

      Affiliations

    • Ingenix i3 Drug Safety, Waltham, MA 02451, USA
    • ,
  • Marie Foegh

      Affiliations

    • Division of Nephrology, Department of Medicine, Georgetown University Medical School, Washington, DC 20057, USA
    • Agile Therapeutics, Inc., Princeton, NJ 08540, USA
    • ,
  • C. Robin Clifford

      Affiliations

    • Ingenix i3 Drug Safety, Waltham, MA 02451, USA
    • ,
  • Jennifer Cutone

      Affiliations

    • Veristat, Inc., Holliston, MA 01746, USA
    • ,
  • Alexander M. Walker

      Affiliations

    • Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    • World Health Information Science Consultants, LLC, Wellesley, MA 02481, USA

Received 10 April 2008; received in revised form 26 June 2008; accepted 27 June 2008. published online 11 August 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ This study was funded by a research contract between Ingenix i3 Drug Safety and Berlex (now a unit of Bayer Health Care). The contract granted i3 Drug Safety oversight of the study conduct, reporting and interpretation, as well as final wording of any resulting manuscripts.

PII: S0010-7824(08)00342-9

doi:10.1016/j.contraception.2008.06.012

Contraception
Volume 78, Issue 5 , Pages 377-383, November 2008

Article Tools

* Image Usage & Resolution